Controlled-release PLGA microsphere containing dexamethasone transforming growth factor and preparation method of controlled-release PLGA microsphere

A technology of transforming growth factor and dexamethasone, which is applied in the fields of medical science and prostheses, can solve the problems that cannot be realized, achieve good tissue compatibility, reduce local inflammatory response, and reduce inflammatory effects
CN104548210AInactive Publication Date: 2015-04-29ZHEJIANG UNIV
1 Cites 5 Cited by

Patent Information

Authority / Receiving Office
CN · China
Current Assignee / Owner
ZHEJIANG UNIV
Publication Date
2015-04-29
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention provides a controlled-release polylactic acid-glycolic acid copolymer microsphere containing a dexamethasone transforming growth factor. A preparation method comprises the following steps: preparing a DEX / PLGA composite microsphere by a water-oil-water emulsion process; positively charging the polylactic acid-glycolic acid copolymer microsphere embedded with DEX through polyethyleneimine of which the surface is covered with positive charges, and mixing TGF-beta3 with a heparin / poly L-lysine solution to form a mixture of which the molar charge ratio is 0-3.15; and mixing TGF-beta3-embedded heparin / poly L-lysine nanoparticles with the PLGA microsphere embedded with the DEX, and covering to obtain the microsphere. The growth-promoting proliferation differentiation action of the growth factor and the anti-inflammatory action of the DEX are compounded; the inflammatory effects caused by a cell attachment carrier are reduced; the controlled-release polylactic acid-glycolic acid copolymer microsphere relatively adapts to cell attachment; the controlled-release polylactic acid-glycolic acid copolymer microsphere is nontoxic and harmless to a living body; a cell scaffold can be degraded by the living body after being treated, and can be used as a carrier for preparing a biological scaffold.
Need to check novelty before this filing date? Find Prior Art

Description

Technical field

[0001] The invention is a biological tissue engineering cell stent material, which involves the method of surface modification of biomass materials. It especially involves a controllable mitochromic acid-hydroxyl acid-hydroxyl acid-hydroxyl acid (TGF-β3) converted growth factor (TGF-β3).PLGA) Micro balls and preparation methods. Background technique

[0002] Many research teams have used myeloplasmic cells or mesenchymal stem cell composite cell stents for research on intervertebral disc tissue projects.In the assessment of biological stent materials, solid -state and pre -molded cell stents include mesh brackets and fiber grids.However, when these cell stents are used to transplant cells, open incisions are required to be implanted in intervertebral discs, destroying the natural closed micro -environment of the intervertebral disc, so the defect is obvious.At the same time, this type of cell bracket is mostly agar, hyaluronic acid, etc., although harmless to biol...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More